Literature DB >> 22595372

Alzheimer's disease: biological aspects, therapeutic perspectives and diagnostic tools.

M Di Carlo1, D Giacomazza, P L San Biagio.   

Abstract

Alzheimer's disease (AD) is the most common form of dementia among older people. Dementia is an irreversible brain disorder that seriously affects a person's ability to carry out daily activities. It is characterized by loss of cognitive functioning and behavioral abilities, to such an extent that it interferes with the daily life and activities of the affected patients. Although it is still unknown how the disease process begins, it seems that brain damage starts a decade or more before problems become evident. Scientific data seem to indicate that changes in the generation or the degradation of the amyloid-b peptide (Aβ) lead to the formation of aggregated structures that are the triggering molecular events in the pathogenic cascade of AD. This review summarizes some characteristic features of Aβ misfolding and aggregation and how cell damage and death mechanisms are induced by these supramolecular and toxic structures. Further, some interventions for the early diagnosis of AD are described and in the last part the potential therapeutic strategies adoptable to slow down, or better block, the progression of the pathology are reported.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22595372     DOI: 10.1088/0953-8984/24/24/244102

Source DB:  PubMed          Journal:  J Phys Condens Matter        ISSN: 0953-8984            Impact factor:   2.333


  27 in total

Review 1.  Nanotechnology-based drug delivery systems for targeting, imaging and diagnosis of neurodegenerative diseases.

Authors:  Sibel Bozdağ Pehlivan
Journal:  Pharm Res       Date:  2013-10       Impact factor: 4.200

2.  Amyloid beta peptide 22-35 induces a negative inotropic effect on isolated rat hearts.

Authors:  Neda Yousefirad; Ziya Kaygısız; Yasemin Aydın
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2016-12-25

3.  Evaluating disease-modifying agents: a simulation framework for Alzheimer's disease.

Authors:  Shien Guo; Denis Getsios; Nikhil Revankar; Peng Xu; Gwilym Thompson; Joel Bobula; Loretto Lacey; Maren Gaudig
Journal:  Pharmacoeconomics       Date:  2014-11       Impact factor: 4.981

Review 4.  A Review of Melatonin, Its Receptors and Drugs.

Authors:  Mucahit Emet; Halil Ozcan; Lutfu Ozel; Muhammed Yayla; Zekai Halici; Ahmet Hacimuftuoglu
Journal:  Eurasian J Med       Date:  2016-06

Review 5.  CUG-BP, Elav-like family (CELF)-mediated alternative splicing regulation in the brain during health and disease.

Authors:  Andrea N Ladd
Journal:  Mol Cell Neurosci       Date:  2012-12-14       Impact factor: 4.314

6.  Amyloid β peptides modify the expression of antioxidant repair enzymes and a potassium channel in the septohippocampal system.

Authors:  Jorge Durán-González; Edna D Michi; Brisa Elorza; Miriam G Perez-Córdova; Luis F Pacheco-Otalora; Ahmed Touhami; Pamela Paulson; George Perry; Ian V Murray; Luis V Colom
Journal:  Neurobiol Aging       Date:  2013-03-07       Impact factor: 4.673

7.  Oligomeric α-synuclein and β-amyloid variants as potential biomarkers for Parkinson's and Alzheimer's diseases.

Authors:  Stephanie M Williams; Philip Schulz; Michael R Sierks
Journal:  Eur J Neurosci       Date:  2015-10-15       Impact factor: 3.386

8.  Stress-induced localization of HSPA6 (HSP70B') and HSPA1A (HSP70-1) proteins to centrioles in human neuronal cells.

Authors:  Sam Khalouei; Ari M Chow; Ian R Brown
Journal:  Cell Stress Chaperones       Date:  2013-09-06       Impact factor: 3.667

9.  Standardized Herbal Formula PM012 Decreases Cognitive Impairment and Promotes Neurogenesis in the 3xTg AD Mouse Model of Alzheimer's Disease.

Authors:  Minsook Ye; Hwan-Suck Chung; Yong Ho An; Su-Jin Lim; Won Choi; A Ram Yu; Jin Su Kim; Manho Kang; Seunghun Cho; Insop Shim; Hyunsu Bae
Journal:  Mol Neurobiol       Date:  2015-10-07       Impact factor: 5.590

Review 10.  Unveiling the role of melatonin MT2 receptors in sleep, anxiety and other neuropsychiatric diseases: a novel target in psychopharmacology.

Authors:  Stefano Comai; Gabriella Gobbi
Journal:  J Psychiatry Neurosci       Date:  2014-01       Impact factor: 6.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.